The major molecular response rate was 68% with asciminib and 49% with IS-TKIs (difference, 19% [95% CI, 10-28]; P .001). The Food and Drug Administration (FDA) has granted accelerated approval to ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

Bosutinib approved for chronic myelogenous leukemia The FDA has approved bosutinib (Bosulif, Pfizer) for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML, who are ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to asciminib for the treatment of adults with newly diagnosed Philadelphia ...

(RTTNews) - Novartis (NVS) announced that Scemblix (asciminib) was granted accelerated approval by the US Food and Drug Administration for adult patients with newly diagnosed Philadelphia ...

A team of Mexican researchers reports on the poor outcomes of a large series of Mexican patients with chronic myeloid leukaemia (CML) in blast phase. This chart review included 51 blast-phase CML ...

Imatinib is recommended as an option for the treatment of people with Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) who initially present in the accelerated phase or with blast ...